[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:solid-neoplasm:ras-family-oncogene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Solid Neoplasm","RAS Family Oncogene",12,[8,16,22,29,35,41,47,53,59,66,72,78],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06299839","PAS-004 in Patients With Advanced Solid Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:15:45.413021Z","2026-05-05T02:43:29.322222Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06884618","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)",[12],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:27.591431Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06162221","Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC",[26],"Phase 1\u002FPhase 2","2026-08-26T02:18:51.833592Z","2026-05-05T02:43:26.935632Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06983743","A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors",[12],"2026-08-26T02:18:21.216897Z","2026-07-05T03:45:20.456891Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05379985","Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS",[26],"2026-08-26T02:17:49.709549Z","2026-05-05T02:43:29.015195Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06804824","A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:17:13.277148Z","2026-05-05T02:43:28.192980Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06326411","A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors",[12],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:27.481677Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT07397338","Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors",[26],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:26.800389Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":64,"content_modified":65},"NCT05512208","A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib",[63],"Phase 2","2026-08-26T02:15:27.567165Z","2026-05-05T02:43:29.586102Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT05111561","Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced\u002FMetastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer",[12],"2026-08-26T02:17:47.813245Z","2026-07-24T01:27:14.906567Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT07638371","A Study of MSK-TCR5 in People With Solid Tumor Cancers",[12],"2026-08-26T02:18:29.369233Z","2026-06-14T18:39:22.257001Z",{"nct_id":79,"title":80,"phases":81,"status":82,"updated_at":83,"content_modified":84},"NCT06507306","A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:23:21.062956Z","2026-04-29T02:57:57.103001Z"]